Recently, luteolin was reported to inhibit bladder cancer cell viability and induce G2/M cell cycle arrest via upregulation of p21/WAF1 and reduction of phosphorylated S6 (p-S6), a key downstream molecule in the mechanistic target of rapamycin (mTOR) signaling pathway. Here, MTOR is linked to urinary bladder carcinoma.